SKP2 and gastric cancer: Given the previous studies that demonstrated that S-phase kinase-associated protein 2 (SKP2) and Cullin1 (CUL1) were tightly connected with the progression of gastric cancer,2, 3, 4 the neddylation inhibitor MLN4924, specifically suppressing the functions of the SKP2-CUL1-F-box (SCF) complexes by blocking the CUL1 neddylation, is therefore a promising drug for the chemotherapy of gastric cancer.5